natgillin/translations-raw huggingface dataset:
During treatment with Seebri Breezhaler, stop taking this medicine and tell your doctor immediately: if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Seebri Breezhaler (signs of bronchospasm).
Med zdravljenjem z zdravilom Seebri Breezhaler, takoj prenehajte uporabljati to zdravilo in obvestite zdravnika: če vas začne takoj po uporabi zdravila Seebri Breezhaler stiskati v prsih, če začnete kašljati, če vam v pljučih piska ali vam zmanjkuje sape (to so znaki bronhospazma),
During treatment with Siklos, blood counts must be monitored every two weeks at treatment initiation (i.e. for the first two months) and if the daily dose of hydroxycarbamide is up to 35 mg/kg b.w.
Med zdravljenjem z zdravilom Siklos je treba na začetku zdravljenja (t.j. prva dva meseca) in, če dnevni odmerek hidroksikarbamida znaša do 35 mg/kg TM, kontrolirati krvno sliko na vsaka dva tedna.
During treatment with sofosbuvir in combination with ribavirin or with peginterferon alfa and ribavirin, the most frequently reported adverse drug reactions were consistent with the expected safety profile of ribavirin and peginterferon alfa treatment, without increasing the frequency or severity of the expected adverse drug reactions.
Med zdravljenjem s sofosbuvirjem v kombinaciji z ribavirinom ali s peginterferonom alfa in ribavirinom so bili neželeni učinki zdravila, o katerih so najpogosteje poročali, skladni s pričakovanim profilom varnosti zdravljenja z ribavirinom in peginterferonom alfa, brez povečanja pogostnosti ali resnosti pričakovanih neželenih učinkov zdravila.
During treatment with Tamiflu, tell a doctor immediately: if you notice changes in behaviour or mood (neuropsychiatric events), especially in children and adolescents).
Med zdravljenjem z zdravilom Tamiflu takoj obvestite zdravnika: če ste opazili spremembe v obnašanju ali razpoloženju (nevropsihiatrični dogodki), še posebej pri otrocih in mladostnikih.
During treatment with Tasigna if you faint (loss of consciousness) or have an irregular heart beat while taking Tasigna, tell your doctor immediately as this may be a sign of a serious heart condition.
V času zdravljenja z zdravilom Tasigna če v času jemanja zdravila Tasigna kdaj omedlite (izgubite zavest) ali če pride do nepravilnega bitja srca, takoj povejte svojemu zdravniku, ker je to lahko znak resne bolezni srca.
During treatment with teriflunomide the following should be monitored:
Med zdravljenjem s teriflunomidom je treba spremljati naslednje:
During treatment with this medicine in combination therapy with an alpha interferon, dental and gum disorders, which may lead to loss of teeth, have been reported.
Med zdravljenjem s kombinirano terapijo s tem zdravilom in enim od alfa interferonov so poročali o zobnih boleznih in boleznih dlesni, ki lahko vodijo do izgube zob.
During treatment with this medicine in combination therapy with an alpha interferon, dental and gum disorders, which may lead to loss of teeth, have been reported.
Med zdravljenjem s kombinirano terapijo s tem zdravilom in enim od alfa interferonov, so poročali o zobnih boleznih in boleznih dlesni, ki lahko vodijo do izgube zob.
During treatment with this medicine:
Med zdravljenjem s tem zdravilom:
During treatment with Torisel, vaccination may be less effective.
Med zdravljenjem z zdravilom Torisel je lahko cepljenje manj učinkovito.
During treatment with Tovanor Breezhaler, stop taking this medicine and tell your doctor immediately: if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Tovanor Breezhaler (signs of bronchospasm).
Med zdravljenjem z zdravilom Tovanor Breezhaler, takoj prenehajte uporabljati to zdravilo in obvestite zdravnika: če vas začne takoj po uporabi zdravila Tovanor Breezhaler stiskati v prsih, če začnete kašljati, če vam v pljučih piska ali vam zmanjkuje sape (to so znaki bronhospazma),
During treatment with Tractocile, your contractions and your unborn baby’s heart rate may be monitored.
Med zdravljenjem z zdravilom Tractocile bodo po potrebi nadzirali kontrakcije vaše maternice in srčno frekvenco ploda.
During treatment with Ultibro Breezhaler
Med zdravljenjem z zdravilom Ultibro Breezhaler
During treatment with Ulunar Breezhaler
Med zdravljenjem z zdravilom Ulunar Breezhaler
During treatment with Velmetia, your doctor will check your kidney function at least once a year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening
Med zdravljenjem z zdravilom Velmetia vam bo zdravnik preveril delovanje ledvic vsaj enkrat na leto ali pogosteje, če ste starejši ali če je delovanje vaših ledvic na meji normalnega ali če obstaja tveganje za poslabšanje.
During treatment with Vistide you should receive regular follow-up eye examinations for possible eye irritation, inflammation or swelling.
Med zdravljenjem z zdravilom Vistide morate redno opravljati preglede oči zaradi morebitnega draženja, vnetja ali otekanja oči.
During treatment with Voncento in adults and adolescents the following adverse reactions may occur: Hypersensitivity or allergic reactions, thromboembolic events, pyrexia, headache, dysgeusia and abnormal liver function test levels.
Med zdravljenjem z zdravilom Voncento pri odraslih in mladostnikih se lahko pojavijo naslednji neželeni učinki: preobčutljivostne ali alergijske reakcije, trombembolični dogodki, zvišana telesna temperatura, glavobol, disgevzija in nenormalni rezultati preiskav jetrne funkcije.
During treatment with Xoterna Breezhaler
Med zdravljenjem z zdravilom Xoterna Breezhaler
During treatment with Zebinix dose adjustment is recommended in patients with creatinine clearance <60 ml/min (see section 4.2).
Pri bolnikih s kreatininskim očistkom < 60 ml/min, je med zdravljenjem z zdravilom Zebinix priporočeno prilagoditi odmerek (glejte poglavje 4.2).
During treatment your doctor will take blood samples regularly to check for changes in your white blood cells (cells that fight infection), red blood cells (cells that carry oxygen), platelets (blood clotting cells), liver function, glucose (blood sugar levels) or changes in other laboratory values.
Med zdravljenjem vam bo zdravnik redno pregledoval kri, da bo lahko spremljal spremembe belih krvnih celic (celice, ki se borijo proti infekcijam), rdečih krvnih celic (celice, ki prenašajo kisik), krvnih ploščic (celice za strjevanje krvi), delovanje jeter, spremembe ravni glukoze (sladkorja v krvi) ali drugih laboratorijskih vrednosti.
During treatment, after complete consumption of the medicated water, animals must be allowed access to unmedicated drinking water as soon as possible.
Ko živali med zdravljenjem porabijo vso medicirano vodo, jim je treba čim prej dovoliti dostop do nemedicirane vode za pitje.
During treatment, after complete consumption of the medicated water, the animals must be allowed access to unmedicated drinking water as soon as possible.
Ko živali med zdravljenjem porabijo vso medicirano vodo, jim je treba čim prej omogočiti dostop do vode za pitje.
During treatment, blood pressure, serum potassium, fluid retention (weight gain, peripheral oedema), and other signs and symptoms of congestive heart failure should be monitored every 2 weeks for 3 months, then monthly thereafter and abnormalities corrected.
Med zdravljenjem je treba v prvih treh mesecih zdravljenja na vsaka dva tedna, nato pa enkrat na mesec spremljati krvni tlak, koncentracijo kalija v serumu, zastajanje tekočin (pridobivanje telesne mase, periferni edem) ter druge znake in simptome kongestivnega srčnega popuščanja in odpravljati nepravilnost.
During treatment, blood tests will be done in the following time intervals:
Med zdravljenjem boste opravljali krvne preiskave v naslednjih intervalih:
During treatment, every 4 weeks except in case of confirmed tubal sterilisation
med zdravljenjem vsake 4 tedne razen v primeru sterilizacije jajcevodov,
During treatment, if you develop a lung infection, tell your doctor so that he can treat the infection.
Če se med zdravljenjem razvije okužba pljuč, to povejte zdravniku, da bo lahko okužbo zdravil.
During treatment, other infections, linked to a weakened immunity (opportunistic infections) may arise.
Med zdravljenjem se lahko pojavijo druge okužbe (oportunistične okužbe), povezane z oslabelo imunostjo.
During treatment, patients receiving Gilenya should be instructed to report symptoms of infection to their physician.
Bolnikom, ki prejemajo zdravilo Gilenya, je treba naročiti, da v času zdravljenja obvestijo svojega zdravnika, če opazijo simptome okužbe.
During treatment, regular blood tests are needed to adjust the daily dose.
Med zdravljenjem so potrebne redne krvne preiskave za prilagoditev dnevnega odmerka.
During treatment, your doctor will check you for signs of scoliosis, a type of spinal deformity.
Med zdravljenjem vas bo zdravnik pregledal, da ugotovi morebitne znake skolioze, vrste deformacije hrbtenice.
During treatment, your doctor will check your blood periodically for levels of several substances such as magnesium, calcium, potassium and phosphate.
Zdravnik bo v času vašega zdravljenja periodično preverjal ravni različnih snovi, kot so magnezij, kalcij, kalij in fosfati v vaši krvi.
During TRISENOX treatment, 14 of the 52 patients in the APL studies had one or more symptoms of APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis (see section 4.4).
Med zdravljenjem z zdravilom TRISENOX je 14 od 52 bolnikov v študijah akutne promielocitne levkemije imelo enega ali več znakov sindroma diferenciacije APL, za katerega so značilni povišana telesna temperatura, dispneja, pridobivanje telesne mase, pljučni infiltrati in plevralni ali perikardialni izlivi, z levkocitozo ali brez nje (glejte poglavje 4.4).
During use in pump: Use within 7 days
Med uporabo v insulinski črpalki: porabite v 7 dneh.
During use of Eptifibatide Accord, you will be checked carefully for any signs of unusual or unexpected bleeding.
Med uporabo zdravila Eptifibatide Accord vas bodo skrbno spremljali, da ugotovijo morebitne znake nenavadne ali nepričakovane krvavitve.
During use of Integrilin, you will be checked carefully for any signs of unusual or unexpected bleeding.
Med uporabo zdravila Integrilin vas bodo skrbno spremljali, da ugotovijo morebitne znake nenavadne ali nepričakovane krvavitve.
During use or when carried as a spare: Levemir FlexPen that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo Levemir FlexPen, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: Levemir FlexTouch that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo Levemir FlexTouch, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoMix 30 FlexPen that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoMix 30 FlexPen, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoMix 30 Penfill that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoMix 30 Penfill, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoMix 50 FlexPen that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoMix 50 FlexPen, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoMix 50 Penfill that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoMix 50 Penfill, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoMix 70 FlexPen that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoMix 70 FlexPen, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoMix 70 Penfill that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoMix 70 Penfill, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoRapid FlexPen that is being used or carried as a spare is not to be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoRapid FlexPen, ki je v uporabi ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoRapid FlexTouch that is being used or carried as a spare is not to be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoRapid FlexTouch, ki je v uporabi ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoRapid InnoLet that is being used or carried as a spare is not to be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoRapid InnoLet, ki je v uporabi ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoRapid Penfill that is being used or carried as a spare is not to be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoRapid Penfill, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
During use or when carried as a spare: NovoRapid PumpCart carried as a spare can be kept for up to 2 weeks below 30°C. Thereafter it can be used for up to 7 days below 37°C in an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps.
Med uporabo in ko se zdravilo uporablja kot rezerva: zdravilo NovoRapid PumpCart, ki ga uporabljate kot rezervo, je lahko shranjeno največ 2 tedna pri temperaturi do 30 °C. Potem ga je mogoče uporabljati največ 7 dni pri temperaturi do 37 °C v insulinskih črpalkah, ki so zasnovane za uporabo s tem vložkom, kot npr. insulinski črpalki Accu-Chek Insight in YpsoPump.
During use or when carried as a spare: NovoRapid PumpCart in use is not to be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo NovoRapid PumpCart, ki ga uporabljate, ne shranjujte v hladilniku.
During use or when carried as a spare: Store below 25°C. Do not refrigerate or freeze.
Med uporabo ali če ima bolnik zdravilo pri sebi za rezervo: shranjujte pri temperaturi do 25 °C. Ne shranjujte v hladilniku in ne zamrzujte.
During use or when carried as a spare: Store below 30°C. Do not refrigerate or freeze.
Med uporabo ali če ima bolnik zdravilo pri sebi za rezervo: shranjujte pri temperaturi do 30 °C. Ne shranjujte v hladilniku in ne zamrzujte.
During use or when carried as a spare: Store below 30°C. Do not refrigerate.
Med uporabo in ko se zdravilo uporablja kot rezerva: shranjujte pri temperaturi do 30 °C. Ne shranjujte v hladilniku.
During use or when carried as a spare: The product can be stored for a maximum of 6 weeks.
Med uporabo ali če ima bolnik zdravilo pri sebi za rezervo: zdravilo je lahko shranjeno največ
During use or when carried as a spare: Use within 4 weeks
Med uporabo ali če ga imate pri sebi za rezervo: porabite v 4 tednih.
During XGEVA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain.
Bolnikom je treba naročiti, da morajo med zdravljenjem z zdravilom XGEVA zdravniku poročati o novi ali nenavadni bolečini v stegnu, kolku ali dimljah.
During year 3, there were no health care contacts for RV gastroenteritis in the vaccine group (n=3,112) and one (non-typeable) in the placebo group (n=3,126).
V tretjem letu zaradi RV gastroenteritisa iz skupine, ki je prejela cepivo (n = 3.112), ni zdravnika obiskal nihče, v skupini, ki je prejela placebo (n = 3.126) pa je bil en (ne-tipiziran) obisk zdravnika.
During your ONIVYDE treatment and one month after you should choose an effective birth control method which suits you, to prevent pregnancy in this period of time.
Med zdravljenjem z zdravilom ONIVYDE in en mesec po tem morate uporabljati vam primerno zanesljivo kontracepcijo, da preprečite zanositev v tem obdobju.
During your treatment with Signifor
V času zdravljenja z zdravilom Signifor
During your treatment with Signifor:
V času zdravljenja z zdravilom Signifor
During your treatment with Thymanax:
Med zdravljenjem z zdravilom Thymanax:
During your treatment with Yondelis you may feel tired and experience a loss of strength.
Med zdravljenjem z zdravilom Yondelis boste morda utrujeni in se počutili šibke.
During Zinbryta treatment, mean cell counts for the major immune subsets (T, B, and NK cells) remained within normal ranges; total lymphocyte, T and B cell counts decreased on average ≤10% from baseline during the first year of treatment.
Med zdravljenjem z zdravilom Zinbryta je ostalo povprečno število celic glavnih imunskih podskupin (celice T, B in naravne celice ubijalke) znotraj normalnih razponov; skupno število limfocitov, celic T in B se je povprečno zmanjšalo za ≤ 10 % od izhodišča v prvem letu zdravljenja.
Dutrebis contains the active substances lamivudine and raltegravir and is only for use in patients whose infection is not resistant to these medicines or certain related antiviral medicines.
Zdravilo Dutrebis vsebuje zdravilni učinkovini lamivudin in raltegravir ter je namenjeno za uporabo le pri bolnikih, katerih okužba ni odporna na ti zdravili ali na določena, z njima povezana protivirusna zdravila.
DUTREBIS film-coated tablets contain lactose
Zdravilo DUTREBIS filmsko obložene tablete vsebuje laktozo.
Dutrebis is a medicine used to treat patients infected with human immunodeficiency virus type 1 (HIV- 1), a virus that causes acquired immunodeficiency syndrome (AIDS).
Zdravilo Dutrebis se uporablja za zdravljenje bolnikov, ki so okuženi z virusom človeške imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
DUTREBIS is not for use in children below 6 years of age.
Zdravila DUTREBIS se ne sme uporabljati pri otrocih mlajših od 6 let.
DUTREBIS is not recommended in pregnancy.
Zdravila DUTREBIS ni priporočljivo uporabljati med nosečnostjo.
Dutrebis lamivudine / raltegravir
Dutrebis lamivudin/raltegravir
DUTREBIS must be used in combination with other medicines for HIV.
Zdravilo DUTREBIS je treba uporabljati skupaj z drugimi zdravili za zdravljenje okužbe z virusom HIV.
DUTREBIS should be used in combination with other active anti-retroviral therapy (ART) (see sections 4.4 and 5.1).
Zdravilo DUTREBIS je treba uporabljati v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavji 4.4 in 5.1).
DUTREBIS should not be given in patients with a creatinine clearance of <50 ml/min (see section 4.2).
Zdravila DUTREBIS ne smejo prejemati bolniki z očistkom kreatinina < 50 ml/min (glejte poglavje 4.2).
DUTREBIS should not be used in children below 6 years of age or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population (see section 5.2).
Zdravila DUTREBIS se ne sme uporabljati pri otrocih, mlajših od 6 let, ali pri bolnikih s telesno maso manj kot 30 kg, ker je treba odmerek v tej populaciji bolnikov določiti glede na telesno maso (glejte poglavje 5.2).
DUTREBIS should not be used in children below 6 years of age or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population.
Zdravila DUTREBIS se ne sme uporabljati pri otrocih, mlajših od 6 let, ali pri bolnikih s telesno maso manj kot 30 kg, ker je treba odmerek v tej populaciji bolnikov določiti glede na telesno maso.
DVFL is slowly formed and more slowly eliminated than vinflunine (t1/2 of approximately 120 h).
DVFL se tvori počasi in se eliminira počasneje od vinflunina (t1/2 približno 120 h).
DVT
GVT
DVT only
samo GVT
DVT) in a lung (i.e.
v pljučih (pljučna embolija)
DVT*
GVT
DXM Cmin not studied
Cmin rifampicina niso preučevali
dying from a heart attack needing an urgent operation to open blocked arteries in the heart.
mrt zaradi srčnega infarkta, potrebo po nujni operaciji za odprtje zamašenih arterij v srcu.
Dynastat 40 mg powder and solvent for solution for injection Parecoxib
Dynastat 40 mg prašek in vehikel za raztopino za injiciranje parekoksib
Dynastat 40 mg powder for injection Parecoxib
Dynastat 40 mg prašek za injiciranje
Dynastat 40 mg powder for solution for injection parecoxib
Dynastat 40 mg prašek za raztopino za injiciranje parekoksib
Dynastat can lead to an increase in blood pressure or worsening of existing high blood pressure which may result in an increase in side-effects associated with heart conditions.
Zdravilo Dynastat povzroči zvišanje krvnega tlaka ali poslabšanje obstoječega zvišanega krvnega tlaka, kar lahko posledično povzroči povečanje neželenih učinkov povezanih z boleznimi srca.
Dynastat contains
Zdravilo Dynastat vsebuje natrij
Dynastat contains the active substance parecoxib.
Zdravilo Dynastat vsebuje zdravilno učinkovino parekoksib.
Dynastat has not been studied in cardiovascular revascularization procedures other than CABG (coronary artery bypass graft procedures).
Zdravilo Dynastat, razen v študijo CABG (operacij obvodov koronarne arterije), ni bilo vključeno v nobeno drugo študijo kardiovaskularnih kirurških postopkov revaskularizacije.
Dynastat is available as a white to off-white powder.
Zdravilo Dynastat je na voljo v obliki belega do belkastega praška.
Dynastat is contraindicated (see section 4.3) in the last trimester of pregnancy.
Zdravilo Dynastat je kontraindicirano v zadnjem trimesečju nosečnosti (glejte poglavje 4.3).
Dynastat is given at a dose of 40 mg, followed by further doses of 20 or 40 mg as required every six to 12 hours, with a maximum dose of 80 mg a day.
Zdravilo Dynastat se daje v odmerku 40 mg, ki mu sledita nadaljnja odmerka po 20 ali 40 mg, odvisno od potrebe, vsakih 6 do 12 ur, vendar ne več kot 80 mg na dan.
Dynastat is not recommended in the first 6 months of pregnancy and you must not receive Dynastat in the last three months of pregnancy.
Zdravilo Dynastat ni priporočljivo v prvih 6 mesecih nosečnosti in zdravila Dynastat ne smete dobiti v zadnjih 3 mesecih nosečnosti.
Dynastat is used for the short-term treatment of pain in adults after an operation.
Zdravilo Dynastat se uporablja za kratkoročno zdravljenje bolečin pri odraslih po operaciji.
Dynastat may be co-administered with opioid analgesics.
Zdravilo Dynastat se lahko uporablja sočasno z opioidnimi analgetiki.
Dynastat must be reconstituted before use.
Zdravilo Dynastat je treba pred uporabo pripraviti.
Dynastat must not be administered to women who breast-feed (see section 4.3).
Zdravila Dynastat doječim ženskam ne smemo dajati (glejte poglavje 4.3).
Dynastat must not be used in patients with severe liver problems.
Zdravilo Dynastat se ne sme uporabljati pri bolnikih s hudo jetrno okvaro.
Dynastat should be administered within 24 hours of reconstitution (see section 6.3), or discarded.
Zdravilo Dynastat je treba aplicirati v 24 urah po pripravi (glejte poglavje 6.3) ali pa ga zavreči.
Dynastat should be used with caution in patients with moderate hepatic dysfunction (Child-Pugh score 7-9) (see section 4.2).
Zdravilo Dynastat moramo uporabljati previdno tudi pri bolnikih z zmerno motnjo delovanja jeter (ocena od 7 do 9 po Child-Pughu) (glejte poglavje 4.2).
Dynastat should not be injected into an IV line delivering any other medicinal product.
Zdravila Dynastat naj se ne aplicira v intravensko pot, v katero apliciramo druga zdravila.